Indications -- Asthma/Allergy Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Indications -- Asthma/Allergy

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who started this subject	6/12/2001 10:43:34 AM
From: nigel bates	of 86

Cambridge Antibody Technology (LSE: CAT: NASDAQ: CATG) today announced that a Phase I clinical trial has commenced of CAT-213, CAT's human monoclonal antibody which neutralises eotaxin1. The Phase I clinical trial will assess safety, tolerability and pharmacokinetics of a single intravenous dose of CAT-213 in 25 healthy volunteers. CAT-213, by neutralising eotaxin1, inhibits the major stimulus that attracts eosinophils (a type of white blood cell) into tissues. As a result of this action CAT-213 may have clinical applications in the treatment of severe allergic disorders where eosinophils may cause tissue damage and in conditions where the patient has too many circulating eosinophils known as hypereosinophilia. Dr David Glover, CAT's Medical Director, said "We are very pleased to announce this milestone for CAT-213, the fifth monocloncal antibody from CAT to enter clinical trials. Data from this first clinical trial will support a trial in allergic patients that we are planning for later this year" CAT-213 CAT-213 is a human IgG4 monoclonal antibody that neutralises eotaxin1 - a chemokine protein that acts to attract eosinophils (a type of white blood cell) into tissues, where they can degranulate causing tissue damage. Eosinophils are thus believed to play a key role in causing the inflammation and tissue damage that occurs in a variety of allergic disorders, including asthma... CAT-213, initially being developed as an intravenous injection, may also be useful in the treatment of other conditions where raised levels of circulating eosinophils play a significant role in pathogenesis (hypereosinophilic syndromes).

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next